Evron Shmuel, Abelansky Yuri, Ezri Tiberiu, Izakson Alexander
Department of Anesthesia, Edith Wolfson Medical Center, Holon, Affiliated with Sackler Medical School, Tel Aviv University, Israel.
Department of Anesthesia, Sieff Medical Center, Faculty of Medicine in the Galilee, Bar-Ilan University, Safed Israel.
Rom J Anaesth Intensive Care. 2017 Oct;24(2):111-114. doi: 10.21454/rjaic.7518.242.evr.
Abdominal surgery in obese patients may be associated with pulmonary morbidity, and mortality. Some patients may arrive in the PACU with residual paralysis. was to find out if there was an association between the type of muscle relaxant reversal agent and the development of postoperative respiratory events in patients undergoing laparoscopic sleeve gastrectomy surgery.
From September 2012 to February 2013, in a prospective randomized pilot study, two different muscle relaxant reversal agents were administered at the end of surgery in 57 patients undergoing laparoscopic sleeve gastrectomy: sugammadex 2 mg/kg (32 patients) vs. neostigmine 2.5 mg (25 patients). We compared the occurrence of early and late respiratory events/complications by the type of reversal agent. Postoperative respiratory rate, oxyhemoglobin saturation (SpO), number of patients with SpO lower than 95% in PACU, the minimum value of SpO in PACU, train-of four counts (TOF) before reversal, unexpected ICU admissions, duration of hospitalization and incidence of reintubation were recorded.
SpO in the PACU was significantly lower in the neostigmine group - 95.80 (± 0.014)) vs. in sugammadex group - 96.72 (± 0.011) (p < 0.01), despite a lower TOF count measured in the sugammadex group reversal, meaning a deeper level of residual relaxation in this group the administration of the reversal agent (2.53 ± 0.98 vs. 3.48 ± 0.58 p < 0.01). Also, the minimal SpO was significantly lower in the PACU in the neostigmine group: 93% vs. 94% (p = 0.01). Respiratory rates were not different. After the administration of reversal, both groups had TOF counts of 4 with no fade assessed visually. There were no postoperative respiratory events or complications.
The use of sugammadex (as compared to neostigmine) as a reversal agent following laparoscopic sleeve gastrectomy surgery was associated with higher postoperative SpO despite the lower TOF count before the administration of reversal agent. Despite the statistical difference in SpO, its clinical importance seems to be minimal. The lack of difference in the other measured variables may stem from the small number of patients studied (pilot).
肥胖患者的腹部手术可能与肺部发病率和死亡率相关。一些患者可能在术后麻醉恢复室(PACU)仍有残余麻痹。本研究旨在探讨在接受腹腔镜袖状胃切除术的患者中,肌肉松弛剂逆转剂的类型与术后呼吸事件的发生之间是否存在关联。
在2012年9月至2013年2月进行的一项前瞻性随机试点研究中,57例接受腹腔镜袖状胃切除术的患者在手术结束时给予两种不同的肌肉松弛剂逆转剂:舒更葡糖2mg/kg(32例患者)与新斯的明2.5mg(25例患者)。我们根据逆转剂的类型比较了早期和晚期呼吸事件/并发症的发生情况。记录术后呼吸频率、氧合血红蛋白饱和度(SpO)、PACU中SpO低于95%的患者数量、PACU中SpO的最小值、逆转前的四个成串刺激计数(TOF)、意外入住重症监护病房(ICU)的情况、住院时间和再次插管的发生率。
新斯的明组在PACU中的SpO显著低于舒更葡糖组——分别为95.80(±0.014)和96.72(±0.011)(p<0.01),尽管舒更葡糖组在给予逆转剂前的TOF计数较低,这意味着该组残余松弛程度更深(2.53±0.98对3.48±0.58,p<0.01)。此外,新斯的明组在PACU中的最低SpO也显著较低:93%对94%(p=0.01)。呼吸频率无差异。给予逆转剂后,两组的TOF计数均为4,视觉上无衰减。术后无呼吸事件或并发症发生。
在腹腔镜袖状胃切除术后使用舒更葡糖(与新斯的明相比)作为逆转剂,尽管在给予逆转剂前TOF计数较低,但术后SpO较高。尽管SpO存在统计学差异,但其临床重要性似乎很小。其他测量变量缺乏差异可能源于研究的患者数量较少(试点研究)。